Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.
Products, services, technology
YB-800 Theranostics Platform targeting a novel, first in class tumor marker for targeted Cancer Therapy.
The Theranostics Platform contains:
- 2 ADCs
- 2 Radiopharmaceuticals
- 2 BiTEs with aCD3 components
- 1 SPECT/PET Scan Diagnostic
- 1 Liquid Biopsy; collaboration with EVIIVE
- 1 Liquid Biopsy Diagnostic
Cooperation possibilities
Open to collaborations with companies who specialize in :
- ADCs
- Radiopharmaceuticals
- Bi-specific Antibodies with aCD3 component
- Tumormarker Diagnostic
- https://www.ymmuno.bio
- +41 76 378 59 30
- Send an email
- Dr. Peter Schiemann, CEO & Chairman of the Board
Some insights
Treatment of Solid Tumors today has still too many short comings. In Therapy and Diagnostic.
Ymmunobio develops new therapies for solid tumor patients to fill the current gaps in available therapy.
Great Team, Great Compounds, Great Partners, Great Investors.
And the prospect of changing solid tumor therapy for patients that today hardly have any options.
James Allison, Tasuku Honjo, Katalin Kariko, Drew Weissman and more...
Because without groundbreaking discoveries there will be no progress in healing patients.
Teamwork, Listening, Entrepreneurial, Decades of Experience in Drug Development, Relationships within the Industry.
In the future we will need a colleague with CMC background and a CMO for sure.
My wife is co-founder of Ymmunobio and with more than 30 years of experience in Drug Development she knows exactly what we are doing.
With contacts to Industry and Investors.
Key business development persons in Pharma that are interested in first in class compounds in oncology.